{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:29:52Z","timestamp":1787567392343,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum der Ruhr-Universit\u00e4t Bochum"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cribriform prostate cancer (cPCa) is increasingly recognized for its aggressive behavior and poor prognosis compared to conventional acinar adenocarcinoma. It is associated with adverse pathological features and excludes patients from active surveillance, highlighting the need for accurate identification. This study aimed to evaluate oncologic outcomes and characterize subsequent treatment patterns in a single-center cohort of patients with cribriform prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials<\/jats:title>\n                    <jats:p>We retrospectively analyzed 401 patients who underwent prostate biopsy and radical prostatectomy (RP) between 01\/2020 and 12\/2021 at a high-volume tertiary center. Of these, 112 patients had cPCa. Data on biopsy and prostatectomy specimens, post-treatment management, biochemical recurrence, and follow-up until August 2025 were collected. Cox regression was used to identify predictors of poor oncologic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 112 patients with cPCa, 66.1% had high-risk disease, and 30.4% had intermediate-risk disease. Biopsy detected 40 cases, with an additional 72 identified in the final post-RP specimen. At diagnosis, 6.3% had metastatic disease. At the time of surgery, 19.2% had lymph node metastases, and 16.4% had positive surgical margins. The median follow-up was 54 months. Univariable analysis showed that high Gleason score (\u2265\u20098), lymph node positivity, and locally advanced stage were associated with decreased systemic therapy-free survival. In metastatic disease, no differences were found in therapy duration or time to castration-resistant prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>cPCa is an aggressive subtype with poor prognosis, characterized by high-risk features and early need for systemic therapy. These findings underscore the need for prospective studies exploring multimodal treatments for this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12672-026-05817-0","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T07:16:16Z","timestamp":1787555776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A single-center study of prognostic impact and treatment implications of cribriform pattern in prostate cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"A.","family":"Handke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Orf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Darr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Roghmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. H.","family":"Tully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"5817_CR1","unstructured":"Cornford P, Tilki D, van den Bergh RCN, Eberli D, De Meerleer G, De Santis M, et al. EAU\u2013EANM\u2013ESTRO\u2013ESUR\u2013ISUP\u2013SIOG Guidelines on Prostate Cancer 2026. European Association of Urology; 2026."},{"key":"5817_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/J.EURURO.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70:106\u201319. https:\/\/doi.org\/10.1016\/J.EURURO.2016.02.028.","journal-title":"Eur Urol"},{"key":"5817_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/S41379-018-0157-9","volume":"32","author":"E Hollemans","year":"2018","unstructured":"Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman J, Roobol MJ, et al. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Mod Pathol. 2018;32:139\u201346. https:\/\/doi.org\/10.1038\/S41379-018-0157-9.","journal-title":"Mod Pathol"},{"key":"5817_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5173\/CEJU.2023.215","volume":"77","author":"R Osiecki","year":"2024","unstructured":"Osiecki R, Kozikowski M, Bia\u0142ek \u0141, Pyzlak M, Dobruch J. The presence of cribriform pattern in prostate biopsy and radical prostatectomy is associated with negative postoperative pathological features. Cent Eur J Urol. 2024;77:22\u20139. https:\/\/doi.org\/10.5173\/CEJU.2023.215.","journal-title":"Cent Eur J Urol"},{"key":"5817_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/S41391-022-00600-Y","volume":"26","author":"GI Russo","year":"2023","unstructured":"Russo GI, Soeterik T, Puche-Sanz I, Broggi G, Lo Giudice A, De Nunzio C, et al. Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26:646\u201354. https:\/\/doi.org\/10.1038\/S41391-022-00600-Y.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5817_CR6","doi-asserted-by":"publisher","first-page":"S477","DOI":"10.21037\/TAU.2018.02.06","volume":"7","author":"O Hassan","year":"2018","unstructured":"Hassan O, Matoso A. Clinical significance of subtypes of Gleason pattern 4 prostate cancer. Transl Androl Urol. 2018;7:S477\u201383. https:\/\/doi.org\/10.21037\/TAU.2018.02.06.","journal-title":"Transl Androl Urol"},{"key":"5817_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/HIS.13767","volume":"74","author":"CF Kweldam","year":"2019","unstructured":"Kweldam CF, van Leenders GJ, van der Kwast T. Grading of prostate cancer: a work in progress. Histopathology. 2019;74:146\u201360. https:\/\/doi.org\/10.1111\/HIS.13767.","journal-title":"Histopathology"},{"key":"5817_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/MODPATHOL.2016.49","volume":"29","author":"CF Kweldam","year":"2016","unstructured":"Kweldam CF, K\u00fcmmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, Van Der Kwast TH, et al. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod Pathol. 2016;29:630\u20136. https:\/\/doi.org\/10.1038\/MODPATHOL.2016.49.","journal-title":"Mod Pathol"},{"key":"5817_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41379-020-0625-x","volume":"34","author":"E Hollemans","year":"2021","unstructured":"Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Osanto S, Pelger RCM, et al. Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. Mod Pathol. 2021;34:184\u201393. https:\/\/doi.org\/10.1038\/s41379-020-0625-x.","journal-title":"Mod Pathol"},{"key":"5817_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/modpathol.2014.116","volume":"28","author":"CF Kweldam","year":"2015","unstructured":"Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, Van Der Kwast TH, Van Leenders GJLH. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol. 2015;28:457\u201364. https:\/\/doi.org\/10.1038\/modpathol.2014.116.","journal-title":"Mod Pathol"},{"key":"5817_CR11","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41379-022-01009-7","volume":"35","author":"E Chan","year":"2022","unstructured":"Chan E, McKenney JK, Hawley S, Corrigan D, Auman H, Newcomb LF, et al. Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25\u00a0mm diameter as an optimal definition for large cribriform prostatic adenocarcinoma. Mod Pathol. 2022;35:1092\u2013100. https:\/\/doi.org\/10.1038\/s41379-022-01009-7.","journal-title":"Mod Pathol"},{"key":"5817_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/PAS.0000000000001384","volume":"44","author":"E Hollemans","year":"2020","unstructured":"Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman J, Roobol MJ, et al. Prostate Carcinoma Grade and Length but Not Cribriform Architecture at Positive Surgical Margins Are Predictive for Biochemical Recurrence after Radical Prostatectomy. Am J Surg Pathol. 2020;44:191\u20137. https:\/\/doi.org\/10.1097\/PAS.0000000000001384.","journal-title":"Am J Surg Pathol"},{"key":"5817_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.urology.2025.01.061","volume":"199","author":"HA de Barros","year":"2025","unstructured":"de Barros HA, Downes MR, Droghetti M, Bekers EM, Giunchi F, Brunocilla E, et al. Prognostic Value of Cribriform and Intraductal Carcinoma in Grade Group 2 Prostate Cancer With and Without Synchronous Nodal Metastases at Radical Prostatectomy: Results From a Case-control Matched, Multicenter Study. Urology. 2025;199:104\u201311. https:\/\/doi.org\/10.1016\/j.urology.2025.01.061.","journal-title":"Urology"},{"key":"5817_CR14","doi-asserted-by":"publisher","first-page":"e70052","DOI":"10.1002\/2056-4538.70052","volume":"11","author":"Y Okubo","year":"2025","unstructured":"Okubo Y, Kasajima R, Sato S, Yamamoto Y, Suzuki A, Aigase T, et al. Cribriform pattern and IDC-P in prostate biopsies: prognostic relevance and reporting in metastatic disease. J Pathol Clin Res. 2025;11:e70052. https:\/\/doi.org\/10.1002\/2056-4538.70052.","journal-title":"J Pathol Clin Res"},{"key":"5817_CR15","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.euf.2023.05.005","volume":"9","author":"R Bernardino","year":"2023","unstructured":"Bernardino R, Sayyid RK, Al-Daqqaq Z, Tiwari R, Cockburn J, Vijayakanthan S, et al. Lymphotropic Pattern of Prostate-specific Membrane Antigen\u2013detected Metastases Among Biochemically Recurrent Radical Prostatectomy Patients with Cribriform Disease. Eur Urol Focus. 2023;9:1016\u201323. https:\/\/doi.org\/10.1016\/j.euf.2023.05.005.","journal-title":"Eur Urol Focus"},{"key":"5817_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/HIS.13893","volume":"75","author":"E Hollemans","year":"2019","unstructured":"Hollemans E, Verhoef EI, Bangma CH, Schoots I, Rietbergen J, Helleman J, et al. Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. Histopathology. 2019;75:338\u201345. https:\/\/doi.org\/10.1111\/HIS.13893.","journal-title":"Histopathology"},{"key":"5817_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.euf.2023.08.010","volume":"10","author":"RM Bernardino","year":"2024","unstructured":"Bernardino RM, Sayyid RK, Lajkosz K, Al-Daqqaq Z, Cockburn JG, Chavarriaga J, et al. Limitations of Prostate Biopsy in Detection of Cribriform and Intraductal Prostate Cancer. Eur Urol Focus. 2024;10:146\u201353. https:\/\/doi.org\/10.1016\/j.euf.2023.08.010.","journal-title":"Eur Urol Focus"},{"key":"5817_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/J.JURO.2017.07.037","volume":"199","author":"M Truong","year":"2018","unstructured":"Truong M, Feng C, Hollenberg G, Weinberg E, Messing EM, Miyamoto H, et al. A Comprehensive Analysis of Cribriform Morphology on Magnetic Resonance Imaging\/Ultrasound Fusion Biopsy Correlated with Radical Prostatectomy Specimens. J Urol. 2018;199:106\u201313. https:\/\/doi.org\/10.1016\/J.JURO.2017.07.037.","journal-title":"J Urol"},{"key":"5817_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/JU.0000000000000526","volume":"203","author":"KJ Ericson","year":"2020","unstructured":"Ericson KJ, Wu SS, Lundy SD, Thomas LJ, Klein EA, McKenney JK. Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance. J Urol. 2020;203:311\u20137. https:\/\/doi.org\/10.1097\/JU.0000000000000526.","journal-title":"J Urol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05817-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05817-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05817-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:08:49Z","timestamp":1787562529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05817-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5817"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05817-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1232"}}